Member Info for extrader

Theanalyzer,

Thanks for this.

Interesting to see that the turnover todate is now reported as 'more than $ 1.0 bn', significantly up from the 'more than $ 750m' reported only 6 weeks ago, when the first tranche of Notes was issued, per https://www.asiaone.com/business/tradeflow-capital-management-announces-inaugural-investment-grade-senior-note-issue,
although confusingly on the same '800+' transactions.

If you take the avge transaction size as $1,000m/800 = $ 1.25m and assume a conservative 90 day cycle, FUM of $ 100m would support 4 x 1.25 = $ 500m of transactions p.a., on the lower reported turnover of $750m, the same FUM would support $ 375m p.a., ie broadly consistent with the Fund's startup (in its current guise) mid 2018.

If the numbers are correct (both presumably sourced from TF), the extra funds should already be leading to significant growth in its business, although arriving too late in 2021 to have much impact.

I guess we'll have to wait for the next trading update to find out more.

lynthip / ASOS : snap ! I had 100,000 @ 5.9p.....

Let the tax tail (disappearance of taper relief) wag the investment dog....

;-<

Hi poorinvester,

If you're interested enough, scroll back through my posts to late March last year, where I posted a 'compare and contrast' on ZIOC vs SYME, explaining why I was invested here but not there....

The rationale is still there, AFAICS.

ATB

Hi poorinvestor.
This seems to be the consensus (2 of us) :
.."Absolutely agree with Extrader. Could be good. Could be not so good..."

Don't know about my 'endless pool' of wisdom (;-<) , but a safe reply might be 'that depends entirely on your personal circumstances'....

IMO, AFAICS, NAI, DYOR etc etc.....

'The dog's too big, so I'll kick the cat'..

Maybe someone's noticed the inconsistency between the UK's much-criticized 'light touch regulation' and its 'overly-cautious' approach to the SPAC market ?

From today's FT

"UK Spac market under scrutiny for safety-first approach
London races to catch up with rivals after City watchdog reforms rules for blank-cheque companies"

Hope springs eternal, etc...

Thanks for this.
Interesting co and connections. Taken with AT's link-up with Mick Davis at Vision Blue, this could also be seen as people preparing for a life after ZIOC.
Which could also be read one of two ways !

Ho hum.

Hi moniman,

I think it might be misleading to get too hung up on the exact name , 'OpenOrphan' : where the 'orphan' bit is just taken to mean a pharma product that hasn't been developed yet, for whatever reason. That could be because early stage, of uncertain application , or because it's not commercially viable (eg a rare condition).

The ORPH core proposition (hVivo + Venn) AIUI is primarily CHIMS and CRO, with 'bits and bobs' thrown in that meet the loose ' not developed yet' tag that morphs into 'not yet commercially exploited/exploitable'. And not just product, I think they use the term to cover 'data'

Under this broader conceptual umbrella, you can then throw in :
- Imutex with flu-v (novel ie unproven delivery approach) and ags-v (broad spectrum 'all mosquito saliva-borne diseases', malaria, dengue, zika etc, again a relatively unproven delivery approach);
- spinout POLB's immunomodulator POLB-001, repurposing from arthritis towards respiratory, see https://www.poolbegpharma.com/pipeline/polb-001/;
- PrepBiopharm, a viral prophylactic, with novel 'nasal delivery' approach; and
- the disease progression database that they hope to exploit commercially , in 2 ways AIUI, first by broad licensing arrangements , via DIM; and secondly via bespoke access transactions for specific 'data mining', similar to what's currently 'in-house' ie the POLB endowment/arrangement.

That's how I think of it, anyway, which works for me as a plausible way of making sense out of the mish-mash !

Very much IMO. Happy for corrections/clarifications /comments.....!

Muchodinero asked the same question elsewhere, my reply there was

.."what happening with the Orphan drug database that Venn was supposed to be selling access to?.."

I think this question is based on a false premise.

Venn's expertise and core competence AIUI lies in the management and resourcing of clinical trials, ie a CRO "offering a unique combination of drug development expertise, clinical trial design and execution services", per its website.

NAI, DYOR etc etc "

HTH

Continuing in the same vein : Hat-tip to Piedro

.."Wow,

Philippines Raises Stakes With Purchase of BrahMos Anti-Ship Missile
PUBLISHED JAN 3, 2022 2:57 PM BY THE MARITIME EXECUTIVE>/font>
hTTps://www.maritime-executive.com/article/philippines-raises-stakes-with-purchase-of-brahmos-anti-ship-missile.."

.."The purchase is the latest of several related capability improvements for the Philippine Navy unveiled in recent weeks. In December, Philippine Defense Secretary Delfin Lorenzana announced the purchase of six patrol ships from Austal for $600 million and two corvettes from Hyundai Heavy Industries for $550 million..."

So that's the thick end of $ 1.2 billion spent on dealing with intruders or other undesirables.

But first you've got to know where they are...

AFAICS.

Peakhope - thanks for clarifying ! I guess that's where the ICC would come in : 'calling on all governments to act'....

ATB

.." if the sace initiative is rolled out around the world - need I say more !!!.."

SACE is the Italian export credit agency https://www.sace.it/en. Export credit agencies are private or quasi-governmental institution that act as an intermediary between national governments and exporters to issue export insurance solutions eg for political risk and guarantees for financing.
SACE doesn't 'roll out' anything overseas, it's a domestic operation, supporting Italian companies : Italian exporters approach it (preferably before concluding a sale to an overseas buyer) and seek cover on a country-by -country basis, which SACE will then OK , if within its criteria, including nature of goods, tenor of finance risk and 'country limit' for amount of insurance it will/can provide.
Thanks to its Italian connections and roots , SYME MIGHT be able to structure some kind of bespoke arrangement with SACE itself, but this won't have any read-across to other ECAs.

IMO

Note the key disclaimer, I'm sure required by the 'adults in the room' - 2 x JC and TJ :

.."no statement in this announcement should be interpreted to mean that the future earnings per share of the Company for current or future financial years will necessarily match or exceed the historical or published earnings per share of the Company..."

EPS is an 'interesting' metric to have chosen, IMO.

ATB

.." if this was going into administrations we would have known..."

How ? Serious question.

Cue : 'No one expects the Spanish Inquisition'.

Happy New Year

The 'guinea pig' is American and the report is about an American company and monulpiravir is a US drug, being developed by Merck pharma and Ridgeback biotherapeutics, so unlikely to involve hVivo, AFAICS.

"Just my thoughts for tomorrow RNS (not advice / DYOR : -"

Well, guidance is that tomorrow's RNS will be a trading update for H2 2021. Actual.
There will likely also be an 'outlook', with all the good things you've suggested. Jam/theoretical.

AIUI.

.."So the company are stating first IM has happened ?..."

No. The relevant bit is just before what you quoted : .."anticipated increase in revenues COMMENCING IN 2022 from each of the three revenue streams .." etc.

I.E no income from IM this year. It's not clear where Due Diligence income (if any this year) will appear.

On the other hand, the RNS refers to 'inventory monetisationS' , so it's expecting more than one, in 2022.

AIUI

It's a 3 month old article that - correct me if I'm wrong - didn't make it to the NCCL twitter feed or other media at the time.

If it wasn't deemed newsworthy then, why should it be considered significant now ?

IMO

Thanks !
Note past co-operation with FMG, from the link :

.."In 2007, the steelmaker cooperated with Australia's FMG to explore the Glacier Valley magnetite block with reserves of 1 billion tonnes (bn t). In 2009, it acquired 15% of the shares of an Australian mining company, Aquila Resources, and became its second-largest shareholder.

In Jun'12, Baowu established Iron Bridge with FMG and merged two iron ore projects in Australia, of which Baosteel accounted for 88% of the shares..."

See also US concern/interest in China's strategic expansion into the Atlantic, via deepwater ports :
https://www.csis.org/analysis/china-building-new-string-pearls-atlantic-ocean

Primarily about Equatorial Guinea, but a lot of the arguments for Bata port there apply equally to Pointe Noire;

along with an interesting overview /US assessment of Congo and Sassou succession + policy recommendations :

https://www.csis.org/node/63156

.."Ambassador Sanders recommends that the Biden administration engage current President Denis Sassou on a two-three-year plan to transition out of office, as well as maintain support for security initiatives in the country..."

Ho hum

Hi hammerphil1989,

Thanks for clarifying. I'm not on twitter.

ATB

And again..."We hear there is an update in the works..."

Source, pls ?